Royalty Pharma plc RPRX
Set alert
66.52 USD -0.66 -0.98%
At close · Nov 2
66.60 +0.08 +0.12%
After hours · Nov 2, 4:00 PM ET
66.43 Day range 67.10
36.03 52-week range 67.71
- YTD
- +72.15%
- 1 year
- +77.20%
- Open
- 66.97
- Prev close
- 67.18
- Mkt cap
- 38.44B
- Vol
- 2.87M
- Avg vol
- 3.08M
- EPS
- 1.88
- P/E
- 35.38
- Div yield
- 1.43%
More statistics
- Low
- 66.43
- High
- 67.10
- Forward P/E
- 11.45
- Beta
- 0.36
- Short ratio
- 4.30
- Inst. own
- 90.20%
- Dividend
- 0.94
- Ex-div date
- Nov 12, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 60.28
- 200-d avg
- 53.22
- 1y target
- 65.38
MAX chart
Events in this range
- Sep 14, 2020Dividend: 0.15
- Nov 19, 2020Dividend: 0.15
- Feb 18, 2021Dividend: 0.17
- May 19, 2021Dividend: 0.17
- Aug 19, 2021Dividend: 0.17
- Nov 18, 2021Dividend: 0.17
- Feb 17, 2022Dividend: 0.19
- May 19, 2022Dividend: 0.19
- Aug 18, 2022Dividend: 0.19
- Nov 17, 2022Dividend: 0.19
- Dec 15, 2022Dividend: 0.19
- Feb 15, 2023Dividend: 0.2
- May 18, 2023Dividend: 0.2
- Aug 17, 2023Dividend: 0.2
- Nov 16, 2023Dividend: 0.2
- Feb 15, 2024Dividend: 0.21
- May 16, 2024Dividend: 0.21
- Aug 16, 2024Dividend: 0.21
- Nov 15, 2024Dividend: 0.21
- Feb 20, 2025Dividend: 0.22
- Feb 21, 2025Dividend: 0.22
- May 16, 2025Dividend: 0.22
- Aug 6, 2025Earnings: 1.14; estimate 1.03; surprise 10.68%
- Aug 15, 2025Dividend: 0.22
- Nov 5, 2025Earnings: 1.17; estimate 0.994; surprise 17.71%
- Nov 14, 2025Dividend: 0.22
- Feb 11, 2026Earnings: 1.46; estimate 1.29; surprise 13.18%
- Feb 20, 2026Dividend: 0.235
- May 6, 2026Earnings: 1.3; estimate 1.21; surprise 7.44%
- May 7, 2026Rating: JP Morgan · Overweight → Overweight
- May 7, 2026Rating: Citigroup · Buy → Buy
- May 15, 2026Dividend: 0.235
- Jul 13, 2026Rating: TD Cowen · Buy → Buy
- Aug 5, 2026Earnings: 1.32; estimate 1.27; surprise 3.94%
- Aug 7, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 14, 2026Dividend: 0.235
- Sep 8, 2026Rating: TD Cowen · Buy → Buy
- Oct 7, 2026Rating: Morgan Stanley · Overweight → Overweight
- Nov 4, 2026Earnings: —; estimate 1.18; surprise —%
Signals (147)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 1 week ago |
| RSI: Overbought | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 7, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| RSI: Overbought | Jan 26, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 19, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 22, 2025 | 10 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| RSI: Overbought | Nov 10, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 3, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
Newest 20 of 147.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 65.38 -1.7% downside
Now 66.52
- Target (low)
- 61.00
- Target (mean)
- 65.38
- Target (high)
- 70.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 1.18 | 1.15 – 1.22 | 1.17 | +0.6% | 884.84M | +8.7% | 6 |
| Next quarter | 1.52 | 1.39 – 1.63 | 1.47 | +3.8% | 941.99M | +7.8% | 5 |
| Current year | 5.32 | 5.17 – 5.44 | 4.83 | +10.2% | 3.51B | +7.7% | 6 |
| Next year | 5.81 | 5.31 – 6.23 | 5.32 | +9.2% | 3.82B | +9.1% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 8, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 7, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 13, 2026 | TD Cowen | Maintained | Buy | Buy |
| May 7, 2026 | Citigroup | Maintained | Buy | Buy |
| May 7, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 21, 2026 | UBS | Maintained | Buy | Buy |
| Apr 10, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jan 30, 2026 | UBS | Upgrade | Neutral | Buy |
| Jan 27, 2026 | Citigroup | Maintained | Buy | Buy |
| Dec 11, 2025 | TD Cowen | Maintained | Buy | Buy |
| Oct 10, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Sep 30, 2025 | Goldman Sachs | Initiated | — | Buy |
| Jul 22, 2025 | Citigroup | Maintained | Buy | Buy |
| Jul 10, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 25, 2024 | Citigroup | Maintained | Buy | Buy |
| Aug 14, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Jul 11, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jun 3, 2024 | UBS | Downgrade | Buy | Neutral |
| Apr 12, 2024 | B of A Securities | Maintained | Buy | Buy |
| Feb 20, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Feb 20, 2024 | Goldman Sachs | Maintained | Buy | Buy |
| Nov 9, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 11, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 9, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 11, 2023 | Morgan Stanley | Reiterated | Overweight | Overweight |
| May 10, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Apr 10, 2023 | Morgan Stanley | Maintained | — | Overweight |
| Apr 6, 2023 | Tigress Financial | Reiterated | — | Buy |
| Feb 16, 2023 | UBS | Maintained | — | Buy |